News related to Afinitor (Everolimus) and/or conditions it is approved for
Novartis drug Afinitor significantly reduces seizures in Phase III study of patients with tuberous sclerosis complex
Source: Epilepsy News From Medical News Today [2016.04.22]
Everolimus is the first adjunctive therapy shown in a prospective randomized Phase III study to achieve clinically significant seizure control in TSC patients1.
FDA OKs New Kids' Dose of Cancer Drug
Source: MedPage Today Product Alert [2012.08.30]
WASHINGTON -- The FDA has approved a pediatric dosage of the cancer drug everolimus (Afinitor Disperz) for the treatment of a rare brain tumor.
New preclinical data show combination of lenvatinib and everolimus yield greater antitumour activity than either agent alone in kidney cancer
Source: Urology / Nephrology News From Medical News Today [2016.04.20]
A preclinical study of lenvatinib plus everolimus1 demonstrates enhanced inhibition of vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF)-induced angiogenesis than for...